 <h1>Tirofiban Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tirofiban: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tirofiban may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking tirofiban:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or swelling</li>
<li>arm, back, or jaw pain</li>
<li>black, tarry stools</li>
<li>blood in the eyes</li>
<li>blood in the urine</li>
<li>bruising or purple areas on the skin</li>
<li>chest pain or discomfort</li>
<li>chest tightness or heaviness</li>
<li>coughing up blood</li>
<li>decreased alertness</li>
<li>fast or irregular heartbeat</li>
<li>headache</li>
<li>joint pain or swelling</li>
<li>nausea</li>
<li>nosebleeds</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding gums</li>
<li>lightheadedness or fainting</li>
<li>pinpoint red spots on the skin</li>
<li>severe, unusual tiredness or weakness</li>
<li>slow heartbeat</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chills or fever</li>
<li>cough</li>
<li>difficulty swallowing</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>skin rash, hives, or itching</li>
<li>trouble breathing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tirofiban may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Pain in the legs or hips</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dizziness</li>
<li>sweating</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tirofiban: intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>Bleeding is the most common adverse reaction.  Clinical trial adverse reactions were reported in patients taking this drug in addition to heparin.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombolysis in myocardial infarction (TIMI) minor bleeding (up to 10.5%)</p>
<p><b>Common</b> (1% to 10%): TIMI major bleeding, transfusions, platelets decreased to less than 90,000 cells/mm3</p>
<p><b>Uncommon</b> (0.1% to 1%): Platelets decreased to less than 50,000 cells/mm3</p>
<p><b>Postmarketing reports</b>: Platelets decreased to less than 10,000 cells/mm3, fatal bleeding<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Vasovagal reaction, dizziness, headache</p>
<p><b>Postmarketing reports</b>: Intracranial bleeding<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Bradycardia, coronary artery dissection</p>
<p><b>Postmarketing reports</b>: Hemopericardium<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p>
<p><b>Postmarketing reports</b>: Retroperitoneal bleeding<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Edema/swelling</p>
<p><b>Postmarketing reports</b>: Spinal epidural hematoma<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Sweating<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Pelvic pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Leg pain<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Postmarketing reports</b>: Severe allergic reactions, anaphylactic reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Pulmonary hemorrhage<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Aggrastat (tirofiban)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about tirofiban</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: glycoprotein platelet inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tirofiban Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Aggrastat</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Coronary Syndrome</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tirofiban: intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>Bleeding is the most common adverse reaction.  Clinical trial adverse reactions were reported in patients taking this drug in addition to heparin.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombolysis in myocardial infarction (TIMI) minor bleeding (up to 10.5%)</p><p><b>Common</b> (1% to 10%): TIMI major bleeding, transfusions, platelets decreased to less than 90,000 cells/mm3</p><p><b>Uncommon</b> (0.1% to 1%): Platelets decreased to less than 50,000 cells/mm3</p><p><b>Postmarketing reports</b>: Platelets decreased to less than 10,000 cells/mm3, fatal bleeding<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Vasovagal reaction, dizziness, headache</p><p><b>Postmarketing reports</b>: Intracranial bleeding<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Bradycardia, coronary artery dissection</p><p><b>Postmarketing reports</b>: Hemopericardium<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p><p><b>Postmarketing reports</b>: Retroperitoneal bleeding<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Edema/swelling</p><p><b>Postmarketing reports</b>: Spinal epidural hematoma<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Sweating<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Pelvic pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Leg pain<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Postmarketing reports</b>: Severe allergic reactions, anaphylactic reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Pulmonary hemorrhage<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Aggrastat (tirofiban)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about tirofiban</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: glycoprotein platelet inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tirofiban Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Coronary Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>